
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 0.46 | 0.46 | 0.00 |
Shares | 98.38 | 98.38 | 0.00 |
Bonds | 1.60 | 1.60 | 0.00 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 14.25 | 21.22 |
Price to Book | 2.92 | 4.03 |
Price to Sales | 1.31 | 2.73 |
Price to Cash Flow | 9.39 | 14.14 |
Dividend Yield | 2.11 | 1.50 |
5 Years Earnings Growth | 8.45 | 10.77 |
Name | Net % | Category Average |
---|---|---|
Technology | 24.47 | 29.42 |
Healthcare | 17.49 | 11.46 |
Consumer Defensive | 13.03 | 5.87 |
Industrials | 13.00 | 9.76 |
Consumer Cyclical | 12.86 | 10.40 |
Financial Services | 10.35 | 14.77 |
Communication Services | 3.41 | 8.98 |
Real Estate | 2.37 | 2.18 |
Basic Materials | 1.41 | 2.39 |
Energy | 1.37 | 3.64 |
Utilities | 0.23 | 2.58 |
Number of long holdings: 236
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Merck & Co Inc | - | 2.79 | - | - | |
Intel Corp | - | 2.75 | - | - | |
Comcast Corp Class A | - | 2.74 | - | - | |
PepsiCo Inc | - | 2.39 | - | - | |
Pfizer Stock | - | 2.34 | - | - | |
United Technologies Corp | - | 2.31 | - | - | |
Medtronic | IE00BTN1Y115 | 2.03 | 96.02 | +0.20% | |
Target Corp | - | 2.02 | - | - | |
Intuit Inc | - | 1.91 | - | - | |
Amgen Inc | - | 1.89 | - | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
GMO Quality III | 11.74B | 12.72 | 24.24 | 16.03 | ||
GMO Quality IV | 11.74B | 12.75 | 24.31 | 16.09 | ||
GMO Quality VI | 11.74B | 12.82 | 24.38 | 16.15 | ||
GMO Benchmark-Free Allocation III | 2.39B | 15.70 | 13.86 | 5.34 | ||
GMO Benchmark-Free Allocation IV | 2.39B | 15.72 | 13.93 | 5.40 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review